(San Diego, Calif., June, 19 2018) — Crown Bioscience, a global drug discovery and development services company providing translational platforms to advance oncology, inflammation, cardiovascular and metabolic disease research, announces that it has been selected by Pierre Fabre Research Institute as one of their partners to advance their immuno-oncology drug discovery pipeline.

Crown Bioscience boasts the world’s largest collection of patient derived xenograft (PDX) models and is a leading provider of humanized solutions for immuno-oncology drug development. Leveraging these exclusive capabilities, Crown Bioscience will engraft PDX models selected by Pierre Fabre into CD34+ humanized mouse models. These customized, humanized models will be used to accelerate Pierre Fabre’s innovative immuno-oncology drug discovery pipeline.

“Pierre Fabre recognizes the value of Crown Bioscience's extensive PDX collection and their expertise in implementing innovative humanization strategies,” said Nathalie Corvaia, Pierre Fabre’s Head of New Biologic Entity Platform and Director of Center of Immunology R&D Pierre Fabre. “We have chosen them as our partner for these reasons and look forward to what we are confident will be a successful alliance.”

“We are very pleased that Pierre Fabre has selected us as a trusted partner to advance their cutting-edge immuno-oncology pipeline,” said Jean-Pierre Wery, Crown Bioscience’s CEO. “Our unique capabilities will enable Pierre Fabre to continue providing new and improved therapies for the treatment of cancer.”

About Crown Bioscience Inc.

Crown Bioscience is a global drug discovery and development solutions company providing translational platforms to advance oncology, inflammation, cardiovascular and metabolic disease research. With an extensive portfolio of relevant models and predictive tools, Crown Bioscience enables clients to deliver superior clinical candidates.

Media Enquiries:

Jody Barbeau
Crown Bioscience Inc.
marketing@crownbio.com